GB Sciences is pleased to announce that its wholly-owned subsidiary, Growblox Life Sciences, LLC has licensed intellectual property from Makai Biotechnology, LLC.
Big pharma is achieving major breakthroughs backed by genetics research, and ultimately more than one human genome sciences stock may benefit.
While major pharmaceutical companies band together to offset the prohibitive costs of Alzheimer’s disease R&D, a new report concludes that medicinal plants may be the most promising treatment for the illness.
Recent acquisitions by Allergan and Teva reflect a broader trend of aggressive M&A by mid-size pharmaceutical companies.
Breakthrough therapies with billion-dollar market potential are what every biotech company seeks—and what every investor wishes for. Narrowing choices and focusing on opportunities with multibagger potential is the goal of every investor, and few do it better than Chen Lin, author of the popular stock newsletter What Is Chen Buying?
OncoGenex Pharmaceuticals is developing solutions to the challenge of overcoming increasing resistance to cancer treatments and offers upside opportunity to investors targeting undervalued biotech stocks.